Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Tian Yuan Healthcare Group's earnings before interest and taxes (EBIT) for the
six
months ended in Dec. 2025 was HK$-32.07 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-36.07 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
China Tian Yuan Healthcare Group's annualizedROC % for the quarter that ended in Dec. 2025 was -6.35%.
China Tian Yuan Healthcare Group's annualizedROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -186.04%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
China Tian Yuan Healthcare Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -17.34%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Tian Yuan Healthcare Group EBIT Related Terms
China Tian Yuan Healthcare Group EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Credit Services subindustry, China Tian Yuan Healthcare Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Tian Yuan Healthcare Group EV-to-EBIT vs Credit Services Industry
For the Credit Services industry and Financial Services sector, China Tian Yuan Healthcare Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where China Tian Yuan Healthcare Group's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-36.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Tian Yuan Healthcare Group (HKSE:00557) has a EBIT of HK$-36.07 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on China Tian Yuan Healthcare Group.
Is China Tian Yuan Healthcare Group's EBIT too high?
China Tian Yuan Healthcare Group's current EBIT is HK$-36.07 Mil. Overall, China Tian Yuan Healthcare Group has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Tian Yuan Healthcare Group's EBIT compare to V and MA?
China Tian Yuan Healthcare Group's EBIT of HK$-36.07 Mil can be compared against companies in the Credit Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Credit Services company?
A good EBIT depends on the Credit Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on China Tian Yuan Healthcare Group. China Tian Yuan Healthcare Group's current EBIT is HK$-36.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Tian Yuan Healthcare Group stock overvalued right now?
Based on GuruFocus' analysis, China Tian Yuan Healthcare Group (HKSE:00557) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.32, compared to a current price of HK$0.55 — trading 70.3% above its estimated fair value. The current EBIT is HK$-36.07 Mil. China Tian Yuan Healthcare Group's overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For China Tian Yuan Healthcare Group (HKSE:00557), the current EBIT is HK$-36.07 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Tian Yuan Healthcare Group (HKSE:00557) Overvalued in 2026?
Based on GuruFocus' analysis, China Tian Yuan Healthcare Group stock appears to be overvalued.
The current stock price of HK$0.55 is trading 70.3% above its estimated GF Value™ of HK$0.32.
GuruFocus considers China Tian Yuan Healthcare Group to be Significantly Overvalued.
Key valuation signals for HKSE:00557:
EBIT: HK$-36.07 Mil
GF Value™: HK$0.32 vs. price of HK$0.55 (70.3% above fair value)
No single metric tells the full story. See the HKSE:00557 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Tian Yuan Healthcare Group Ltd is an investment holding company engaged in investment holding, provision of procurement, marketing and management services to the medical industry, provision of procurement services relating to the hospitality industry, licensing of trademarks, and money lending and related business. Its segments include Investment Holding, Healthcare, Money Lending and Related Business, which generates maximum revenue from interests earned from the provision of loans to third parties, referral and handling fees for loan-related services, and the introduction of prospective lenders and borrowers in PRC and Hong Kong; and Hospitality. The company generates maximum revenue from Hong Kong.
28GF Score
Get the complete analysis for HKSE:00557
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00557 has been successfully added to your 
